Undisclosed PSMA/STEAP1 BsADC / HC Biopharma - LARVOL DELTA

Bispecific antibody with dual-payload ADC for metastatic castration-resistant prostate cancer (AACR 2026) - "The PSMA/STEAP1 BsADC demonstrated optimal affinity, simultaneous binding to both targets, with no observable cross-reactivity to unrelated antigens...This approach mitigates the issue of antigen escape and leverages synergistic payload activity, resulting in superior efficacy against heterogeneous prostate tumors. Our compelling preclinical data warrant further clinical development, and this BsADC represents a promising therapeutic candidate for patients with mCRPC, including those resistant to current ADC therapies."

ADC • Bispecific • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • STEAP1